Clinical Trial Update: Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase II trial of Campath-1H (alemtuzumab) for Waldenström's Macroglobulinemia and Lymphoplasmacytic Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Campath-1H (alemtuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED